DianNei Bio Secures Nearly RMB 10 Million in Angel Funding for AI-Powered Lung Cancer Early Screening Platform 'FeiChangHao'

On August 16, VCBeat learned that PointInside Bio announced the completion of its angel round financing, raising nearly RMB 10 million. The investment was made by Xinyi Capital, with Haoyi Angel serving as the financial advisor. Ge Liang, founder of PointInside Bio, stated that the funds from this round will be primarily used for product optimization and iteration, validation of application scenarios, and engagement with partners.

VCBeat has previously in "Worth Noting! Diannei Biology Leverages AI to Achieve Early Lung Cancer Screening in 3 Minutes》reported that, using a point-of-care biosystem, the risk of lung cancer can be accurately assessed in just three minutes.

Ge Liang told VCBeat: “What has attracted investment institutions is, on the one hand, Diannei Biotech’s data acquisition capability. Through collaborations with top-tier tertiary hospitals in China, Diannei Biotech has amassed a large volume of high-quality data. On the other hand, it is the founding team’s familiarity with and understanding of the healthcare sector. Medical AI represents the integration of healthcare and artificial intelligence technologies; given the complexity of healthcare, it is essential for the founding team to be well-versed in various medical processes to avoid unnecessary detours in later stages.”

Currently, clinical judgment of tumors and the accuracy of imaging reports rely primarily on the accumulated knowledge and experience of oncology experts. Interpretations often vary among physicians across different hospitals, whereas artificial intelligence, trained on large-scale pathological datasets, achieves precision comparable to that of senior experts.

Diannei (Shanghai) Biotechnology Co., Ltd., as a startup, leverages big data and artificial intelligence technologies. By integrating application scenarios from top-tier hospitals in China and collaborating with government regulatory authorities, the company extends its services into communities to conduct AI-driven early screening for lung cancer, thereby helping the public detect and prevent early-stage tumors.

Ge Liang stated that, unlike artificial intelligence technologies that assist radiologists in interpreting medical images, they intend to apply AI at an earlier stage, focusing on lung cancer prevention and even aiding in diagnosis, thereby enabling patients to begin treatment at an earlier stage.

Through automated recognition and deep learning of medical images,Furthermore, validated against the gold standard of pathological reports, its AI technology can provide early warning for lung cancer within just three minutes, achieving an accuracy rate exceeding 80%, which approaches the level of expert performance.。

According to Ge Liang, Diannei Biotech is currently conducting in-depth research on imaging-based morphological analysis, aiming to identify precancerous lesions from low-dose spiral CT scans, differentiate between squamous cell carcinoma and adenocarcinoma, and even assist in tumor staging.

In July 2017, Diannao Biotechnology entered the top tier of the global rankings in the Alibaba Cloud Tianchi Lung Nodule Screening Competition. With continuously improving performance and ranking, the accuracy of lung nodule screening reached 95%. After accounting for factors such as false negatives and false positives, the FROC curve value was 0.741. The company ranked 8th globally in the preliminary round and currently holds 4th place in the semifinal round (out of more than 3,000 participating teams worldwide).

Diannei Bio leverages continuous and comprehensive health data to conduct multi-level value discovery,Starting with structured medical records, medical imaging, and genetic testing, the company will focus internally on research into structured medical records and imaging diagnostics, while outsourcing genetic testing to third-party providers. In the future, it will launch an AI-powered auxiliary diagnostic engine encompassing three dimensions, and carry out clinical applications in the field of oncology, including lung cancer, lymphoma, gastric cancer, and colorectal cancer.。

From a commercial application perspective, the company currently charges industry clients, such as government agencies and insurance companies. These entities require early cancer screening to improve treatment outcomes and control medical insurance costs. With the accumulation of preliminary data, models for early lung cancer screening will become more accurate, thereby generating subsequent commercial value through data monetization.

Currently, Diannei Biotech has signed a cooperation agreement with the Yangpu District Center for Disease Control and Prevention in Shanghai and has begun providing early lung cancer screening services to community residents.

It is understood that Diannei Bio’s AI medical team is about to launch an AI-powered imaging-assisted diagnostic product for real-world clinical application, which will soon achieve comprehensive coverage of medical data for lung cancer screening. During the product’s trial phase, hospitals and physicians using the Diannei Intelligent Imaging-Assisted Diagnostic Platform have already begun incorporating system-generated reports into their diagnostic conclusions. According to system projections, the adoption rate of reports generated by Diannei’s AI imaging-assisted diagnostic system by physicians is expected to reach 90% in the future.